Bicycle Therapeutics Plc Enhances Oncology Focus with New Clinical Advisory Board Members

Bicycle Therapeutics Expands Clinical Advisory Board to Strengthen Oncology Focus

Bicycle Therapeutics plc, a leading pharmaceutical innovator specializing in therapeutics based on its proprietary bicyclic peptide technology, significantly enhances its Clinical Advisory Board (CAB) by welcoming three prominent global oncology experts. This strategic move aims to bolster the company's clinical oncology programs and aligns with Bicycle's mission to develop precision-targeted therapies for cancer patients. CEO Kevin Lee, Ph.D., expresses enthusiasm about the addition of Dr. Howard A. "Skip" Burris, III, Dr. Markus Eckstein, and Dr. Niklas Klümper. Their extensive experience is expected to provide invaluable insight as Bicycle Therapeutics accelerates its innovative pipeline.

Dr. Burris, a recognized leader in the oncology field, serves as the president and chief medical officer at the Sarah Cannon Research Institute. His role in the development of numerous FDA-approved cancer agents and his past presidency at the American Society of Clinical Oncology (ASCO) underscore his influence in advancing cancer care. Meanwhile, Dr. Eckstein, a senior consultant pathologist at the University Hospital Erlangen, brings a wealth of expertise in genitourinary and predictive molecular pathology, along with a focus on systems immunology in cancer. Dr. Klümper, a senior consultant for Urology & GU Oncology at the University Hospital Bonn, leads a research group dedicated to precision oncology, particularly concerning uro-oncology. The collective expertise of these professionals is expected to strengthen Bicycle Therapeutics' research and development initiatives, paving the way for innovative cancer therapies.

In addition to expanding its advisory capabilities, Bicycle Therapeutics recently presented promising data on its investigational drug, zelenectide pevedotin, at the 2024 San Antonio Breast Conference Symposium. This research underscores the drug's potential in treating breast cancer patients with NECTIN4 gene amplification and its efficacy when combined with pembrolizumab for metastatic urothelial cancer (mUC). As the company progresses with its Phase 2/3 Duravelo-2 trial, it aims to target topline results by the second half of 2025. In line with its commitment to advancing oncological therapies, Bicycle plans to initiate Phase 1/2 trials in 2025 for various malignancies associated with NECTIN4 amplification.

Bicycle Therapeutics' multifaceted approach not only emphasizes the importance of collaboration with leading oncology experts but also showcases its dedication to developing innovative cancer therapies. With a conference call scheduled for December 13 to discuss recent findings and strategic directions, the company positions itself as a potential leader in the treatment of cancers associated with the NECTIN4 gene, reinforcing its commitment to improving patient outcomes through advanced therapeutics.